Literature DB >> 2735940

The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo.

M J Lind1, A T McGown, J A Hadfield, N Thatcher, D Crowther, B W Fox.   

Abstract

The effect of ifosfamide and its metabolites on intracellular levels of glutathione in P388 cells in vitro has been studied. It is demonstrated that glutathione depletion occurs only in the presence of 4-hydroperoxyifosfamide and chloroacetaldehyde. In contrast isophosphoramide mustard had no effect on glutathione levels in intact cells. The concentration of 4-hydroperoxyifosfamide required to reduce glutathione levels by 50% was approximately 1 mM and this represents a concentration far in excess of that achievable in patients receiving the drug. However the concentration of chloroacetaldehyde (approximately 100 microM) required to reduce intracellular levels of glutathione to a similar extent is attained in patients receiving ifosfamide. The glutathione levels in lymphocytes isolated from a patient undergoing an eight hour infusion of ifosfamide showed a marked decrease to about 30% of their original value. We conclude that ifosfamide causes glutathione depletion in vivo and the majority of this can be accounted for by the production of chloroacetaldehyde.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2735940     DOI: 10.1016/0006-2952(89)90419-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  21 in total

1.  Mesna or cysteine prevents chloroacetaldehyde-induced cell death of human proximal tubule cells.

Authors:  Gerald Schwerdt; Antje Kirchhoff; Ruth Freudinger; Brigitte Wollny; Andreas Benesic; Michael Gekle
Journal:  Pediatr Nephrol       Date:  2007-02-02       Impact factor: 3.714

2.  Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions.

Authors:  Benigno C Valdez; Moustapha Hassan; Borje S Andersson
Journal:  Exp Hematol       Date:  2017-05-04       Impact factor: 3.084

Review 3.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

4.  Effects of Cyclophosphamide and/or Doxorubicin in a Murine Model of Postchemotherapy Cognitive Impairment.

Authors:  Timothy J Flanigan; Julie E Anderson; Ikram Elayan; Antiño R Allen; Sherry A Ferguson
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

5.  2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity.

Authors:  C Sood; P J O'Brien
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 6.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

7.  IEVM chemotherapy with rhGM-CSF support for aggressive non-Hodgkin's lymphomas: a pilot study.

Authors:  J Walther; W Wilmanns; H H Gerhartz
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

8.  Results of chemotherapy using ifosfamide with doxorubicin in advanced breast cancer.

Authors:  M Millward; M Lind; L Gumbrell; A Robinson; T Lennard; B Cantwell
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

9.  The effect of treatment with high dose melphalan, cisplatin or carboplatin on levels of glutathione in plasma, erythrocytes, mononuclear cells and urine.

Authors:  L Hogarth; M English; L Price; R Wyllie; A D Pearson; A G Hall
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

10.  Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.

Authors:  C Kosmas; N Mylonakis; G Tsakonas; G Vorgias; N Karvounis; N Tsavaris; T Daladimos; N Kalinoglou; N Malamos; T Akrivos; A Karabelis
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.